Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer
- 1 November 2016
- journal article
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 108, 168-179
Abstract
No abstract availableKeywords
Funding Information
- Department of Defense (DOD) Breast Cancer ProgramDepartment of Defense (DOD) Breast Cancer Program (W81XWH-11-1-0211)
- National Institute on Minority Health and Health Disparities (NIMHD) P20 programNational Institute on Minority Health and Health Disparities (NIMHD) P20 program (1P20MD006738-03)
- National Institutes of Health (NIH) SC-1 grantNational Institutes of Health (NIH) SC-1 grant (5SC1CA161676-03)
This publication has 37 references indexed in Scilit:
- Chemoprevention of Skin Cancer with 1,1-Bis (3′-Indolyl)-1-(Aromatic) Methane Analog through Induction of the Orphan Nuclear Receptor, NR4A2 (Nurr1)PLOS ONE, 2013
- AlgiMatrix™ Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer StudiesPLOS ONE, 2013
- Therapeutic Roles of Curcumin: Lessons Learned from Clinical TrialsThe AAPS Journal, 2012
- 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancerBMC Cancer, 2010
- Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriersJournal of Controlled Release, 2010
- Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis(3′-indoly)-1-(p-substituted phenyl)methanesMolecular Cancer Therapeutics, 2008
- Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3,3′-Diindolylmethane in Healthy SubjectsCancer Epidemiology, Biomarkers & Prevention, 2008
- 1,1-Bis(3′-Indolyl)-1-(p-Substitutedphenyl)methanes Induce Apoptosis and Inhibit Renal Cell Carcinoma GrowthClinical Cancer Research, 2007
- 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathwaysBreast Cancer Research and Treatment, 2007
- Single-Dose and Multiple-Dose Administration of Indole-3-Carbinol to Women: Pharmacokinetics Based on 3,3′-DiindolylmethaneCancer Epidemiology, Biomarkers & Prevention, 2006